Tumor-associated antigen L523S (L523S)

Tumor-associated antigen L523S is an **oncofetal RNA-binding protein** that belongs to the KOC family. It is normally expressed during early embryonic development but becomes re-expressed at high levels in a significant proportion of non-small cell lung carcinomas—particularly squamous cell subtypes—while being largely absent from most adult tissues. This restricted expression pattern makes it a promising target for cancer immunotherapy strategies such as therapeutic vaccination. L523S has been shown to be both **tumor-specific and immunogenic**, with evidence that some patients naturally develop antibody responses against it during malignancy. Its biological role includes regulation of mRNA stability and translation; specifically, it may facilitate insulin-like growth factor II mRNA function—a process implicated in oncogenesis. Experimental therapies using recombinant DNA vaccines encoding the full-length or partial sequence of the **L523S gene** have demonstrated induction of specific cytotoxic T lymphocyte responses against tumors expressing this antigen. These findings support its candidacy as both a biomarker for disease progression and as an immunotherapeutic target in NSCLC. Safety data from early-phase studies indicate minimal toxicity at tested vaccine doses.[1][2][8][9][10]

Other names

L523SOncofetal RNA-binding protein L523SKOC family RNA-binding protein (contextual, not a standard alias)

For DNA vaccines targeting this molecule: Induction of cytotoxic T lymphocyte (CTL) responses against tumor cells expressing the L523S antigen, aiming to break immune tolerance and stimulate anti-tumor immunity.[8][9][1]